S5-E12.2 – MASH Drug Development: Improving Efficacy Endpoints
Sven Francque and William Alazawi join the Surfers to discuss challenges in proper scoring and categorization of efficacy endpoints during MASH Drug Development.
April 27, 2024
Sven Francque and William Alazawi join the Surfers to discuss challenges in proper scoring and categorization of efficacy endpoints during MASH Drug Development.
Sven Francque joins guest William Alazawi and the Surfers to discuss high points from his 2023 article on the MASH drug development graveyard in 2023
Sven Francque and William Alazawi join the Surfers to to consider how we have translated the lessons of previous failed trials into better designs that produce successful trials.
This 2023 conversation raises the question of prescribing MASH drugs adjunctive to other therapies, most notably HCC.
This final conversation touches on prescribing models and the increasing challenge keeping patients in long-term clinical trials, after which Roger Green asks a final question.
This conversation includes the rest of the panelists’ hot topics plus Michael Charlton’s dive into FGF-21s.
Michael Charlton joins the Surfers for a far-reaching conversation, with topics ranging from how his clinic is integrating Rezdiffra in MASH patient treatment to exciting research, both reported and in development.
Fatty Liver Alliance Founder Mike Betel joins Roger Green to consider how patient incentives to participate in MASH clinical trials might need to change now that prescribers have an approved drug for treating MASH patients.
MASLD patient advocates consider new needs and opportunities for other stakeholders after the Rezdiffra approval and launch.
Last Thursday, March 14, Rezdiffra (resmetirom) became the first drug approved in the US for MASH. Five leading North American MASLD patient advocates join the Surfers to discuss their feelings about this approval along with the opportunities and challenges that lie ahead.